Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia
Hervé Dombret(University of London Institute in Paris), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Andrew H. Wei(The Royal Melbourne Hospital), Qui Tran(Amgen (United States)), Simon Durrant(Royal Brisbane and Women's Hospital), Zachary Zimmerman(Amgen (United States)), Max S. Topp(Universitätsklinikum Würzburg), Christopher Larry Bacon(St. James's Hospital), Andre C. Schuh(University of Toronto)
Cited by 64
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k